References
- Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging, Journal of Nuclear Cardiology. 2020; 27 (2): 659–73.
- Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2—Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology. 2020; 28(4): 1769–74.
- Adam R, Stan C, Onciul S, et al. Amiliodoza cardiacă – o sinteză pentru cardiologii practicieni. StetoscopCardio. 2019, pg12-16.
- O'Malley J, Thrall JH, Ziessman H, et al. The Requisites, 5th Edition, Nuclear medicine and molecular imaging, 2021, Elsevier 1600, John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899, NUCLEAR MEDICINE AND MOLECULAR IMAGING: THE REQUISITES, 5th EDITION ISBN: 978-0-323-530378.
- De Michieli L, Omar F. Ezzeddine A, Abbasi MA, et al. Biomarkers to predict abnormal Technetium-99m Pyrophosphate scans in patients with suspected transthyretin amyloidosis. JACC Cardiooncology 2025; 7 (1): 70-78.
- Rettl R, Duca F, Kronberger C, et al. Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 2025; 26 (2): 251–260.
- Delbarre MA, Chadha GD, Annabi MS, et al. Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg? J Intern Med. 2025; 297: 186–200.
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management - A scientific statement from the American Heart Association, American Heart Association. 2020; 142: e7–e22.
- Aimo A, Chen YFF, Castiglione V, et al. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev. 2025.
- Laptseva N, Benzabc DC, Schwotzerad R, et al. Cardiac amyloidosis. SwissMed Wkly. 2024; 14: 4186.
- Wang TKM, Abou Hassan OK, Jaber W, et al. Multimodality imaging of cardiac amyloidosis: Contemporary update. World J Radiol. 2020; 12(6): 87-100.
- Sperry BW, Burgett E, Bybee KA, McGhie AI, O'Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol. 2020; 27(5): 1802–7.
- Castano A, HaqM, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar Technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016; 1(8): 880–9.
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019; 73(22): 2872–2891.
- Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, et al. Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis. J AmColl Cardiol Img. 2023; 16(12): 1567–1580.
- Ungericht M, Groaz V, Messner M, Schuetz T, Brunelli L, Zaruba MM, et al. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis. Amyloid. 2024; 31: 22–31.
- Löfbacka V, Axelsson J, Pilebro B, Suhr OB, Lindqvist P, Sundström T. Cardiac transthyretin amyloidosis 99mTc- DPD SPECT correlates with strain echocardiography and biomarkers. Eur J Nucl Med Mol Imaging. 2021; 48: 1822–32.
- Morioka M, Takashio S, Nakashima N, Nishi M, Fujiyama A, Hirakawa K et al. Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2022;11:e024717.
- Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res.2021; 128(10): 1554–75.
- Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020; 27(17): 1806–1815.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021; 42(16): 1554–1568.
- Romero Pabón AJ, Clerc OF, Vijayakumar S, Cuddy SAM, Dorbala S. Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis. Curr Cardiol Rep. 2024; 26(11): 1153–1162.
- Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023; 44(24): 2187–98.
- Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, et al. Management of transthyretin amyloidosis. Swiss Med Wkly. 2021; 151(4142): w30053.